CClinicalTrials.gg
Sign In
CompletedNCT03444584Updated Jan 13, 2020Results posted

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

A Phase 2 interventional study of MEDI0382 and Placebo in Type 2 Diabetes Mellitus, sponsored by MedImmune LLC. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by MedImmune LLC · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 115 Years
Sex
All
01

Study summary

A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2 Diabetes Mellitus (T2DM).

Read the detailed description

This is an exploratory randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MEDI0382 versus placebo in overweight/obese participants with T2DM treated with metformin and dapagliflozin dual therapy. The study will enroll participants with T2DM treated either with metformin monotherapy or with metformin and dapagliflozin dual therapy. After the screening period, participants treated with metformin monotherapy only will enter a 4-week run-in period where participants will be administered oral dapagliflozin 10 mg a day, which will be provided by the sponsor. Enrolled participants that are already treated with metformin and dapagliflozin dual therapy will continue this dual therapy throughout the study and can be randomized after the screening period without entering the run-in period. All participants (ie, on monotherapy and dual therapy) entering the double-blind treatment period will receive dapagliflozin 10 mg a day, which will be provided by the sponsor.

Participants in this study will participate for up to 20 weeks including a screening period of up to 60 days, a 4-week run-in period (for participants on metformin monotherapy only), a 4-week treatment period, and a 4-week follow-up post-treatment period.

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • 0382
  • T2DM
03

Who can participate

Ages eligible
18 Years to 115 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male and female participants aged >= 18 years at screening.
  2. Provision of signed and dated informed consent form (ICF) prior to any study specific procedures.
  3. Body mass index between 25 kg/m\^2 and 40 kg/m\^2 (inclusive) at screening.
  4. Hemoglobin A1c range between 7.0% and 10.0% (inclusive) at the time of screening.
  5. Diagnosed with T2DM and treated with of metformin monotherapy (MTD > 1 g) at least 8 weeks prior to screening or treated with stable, oral doses of dapagliflozin 10 mg and metformin (MTD > 1 g) for at least 3 months prior screening.
  6. Participants prescribed oral dual therapy with sulphonylurea, glitinide, or dipeptidyl peptidase-4 inhibitor (in addition to metformin) may be eligible to enter the study following a washout period of these medications totaling at least 28 days before initial screening evaluations have been completed.
  7. Participants treated with stable doses of metformin (MTD > 1 g) with canagliflozin (maximum dose of 300 mg/day), or metformin (MTD > 1 g) with empaglifozin (maximum dose of 25mg/day) for at least 3 months prior to screening may be eligible to enter the study after switching to dapagliflozin.
  8. Female participants of childbearing potential must have a negative pregnancy test at screening and randomization and must not be lactating.
  9. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female participant to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  1. History of, or any existing condition that in the opinion of the investigator would interfere with evaluation of the investigational product, put the participant at risk, influence the participant's ability to participate, or affect the interpretation of the results of the study and/or any participant unable or unwilling to follow study procedures.
  2. Any participant who has received another investigational product not included in the protocol as part of a clinical trial or a glucagon-like peptide-1 (GLP-1) analogue or sodium-glucose cotransporter-2 (SGLT2)-containing preparation (excluding dapagliflozin, canagliflozin, empagliflozin) within the last 30 days or 5 half-lives of the drug (whichever is longest) at the time of screening.

  3. Any participant who has received any of the following medications prior to the start of the screening period (Visit 1) or prior to the study start period (Visit 4):

    • Concurrent use of any medicinal products, or herbal or over-the-counter (OTC) preparations licensed for control of body weight or appetite at the time of screening (Visit 1)
    • Concurrent or previous use of drugs approved for weight loss (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within the last 30 days or 5 half-lives of the drug (whichever is longest) at the time of screening (Visit 1)
    • Concurrent use of aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 72 hours prior to the start of the study (Visit 4)
    • Concurrent use of paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 72 hours prior to the start of the study (Visit 4)
    • Concurrent use of ascorbic acid (vitamin C) supplements at a total daily dose greater than 1000 mg and within the last 72 hours prior to the start of the study (Visit 4)
    • Concurrent use of opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying and within the last 72 hours prior to the start of the study (Visit 4)
  4. Concurrent participation in another study of any kind and repeat randomization in this study is prohibited.
  5. Severe allergy/hypersensitivity to any of the proposed study treatments or excipients.
  6. Diagnosis of type 1 diabetes mellitus, maturity-onset diabetes of the young, or latent autoimmune diabetes of adulthood or presence of anti-glutamic acid decarboxylase, anti-islet cell, or anti-insulin antibodies.
  7. Symptoms of acutely decompensate blood glucose control (eg, thirst, polyuria, weight loss) at screening or randomization, a history of diabetes ketoacidosis (DKA), or hyperosmolar nonketotic coma or treatment with daily subcutaneous insulin within 90 days prior to screening.
  8. Fasting hyperglycemia (> 250 mg/dL/ > 13.9 mmol/L) prior to randomization.
  9. C-peptide level \< lower limit of normal (LLN).
  10. History of acute or chronic pancreatitis or pancreatectomy.
  11. Hypertriglyceridemia (> 400 mg/dL) at screening.
  12. Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal (GI) tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data.

  13. Significant hepatic disease (except for nonalcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:

    • Aspartate transaminase (AST) >= 3 × upper limit of normal (ULN)
    • Alanine transaminase (ALT) >= 3 × ULN
    • Total bilirubin (TBL) >= 2 × ULN
  14. Impaired renal function defined as estimated glomerular filtration rate (eGFR) \<= 60 mL/minute/1.73m\^2 at screening (eGFR according to Modification of Diet in Renal Disease [MDRD] using the isotope dilution mass spectrometry-traceable MDRD Study Equation (SI units).
  15. Use of loop diuretics within 1 month prior to screening.

  16. Poorly controlled hypertension as defined below:

    • Systolic blood pressure (BP) > 160 mm Hg
    • Diastolic BP or >= 100 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening (Visit 1 for all participants).
  17. Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening.
  18. Severe congestive heart failure (New York Heart Association Class III and IV)
  19. Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
  20. Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration \< 11.5 g/dL [115 g/L] for males and \< 10.5 g/dL [105 g/L] for females) at screening or any other condition known to interfere with interpretation of HbA1c measurement.
  21. History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer.
  22. Any positive results for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.
  23. Recent viral infection or illness requiring the use of antibiotics in the month prior to screening (Visit 1) for participants on dual therapy or prior to run-in period (Visit 2) for participants on monotherapy.
  24. History of recurrent (at least 2) urinary tract and/or genital tract infections (including mycotic infections such as thrush) within 6 months prior to screening.
  25. Substance dependence likely to impact participant safety or compliance with study procedures.
  26. Involvement of any AstraZeneca, MedImmune, contract research organization, or study site employees and their close relatives.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    MEDI0382

    Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.

    Drug: MEDI0382 · Drug: Dapaglifozin · Drug: Metformin

  • Placebo comparator
    Placebo

    Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period

    Drug: Placebo · Drug: Dapaglifozin · Drug: Metformin

Interventions

  • DrugMEDI0382

    Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).

  • DrugPlacebo

    Subcutaneous dose of placebo matched to MEDI0382.

  • DrugDapaglifozin

    Oral dose of dapaglifozin 10 mg tablet.

  • DrugMetformin

    Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).

05

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT)

    The MMTT test involved the consumption of a standardised liquid meal (nutritional supplement of fat, carbohydrate, and protein) within 5 minutes. On Day -1 and on Day 28, following a minimum 10 hour fast, serial of blood samples were obtained prior and through 240 minutes after consumption of standardized meal for the measurement of glucose metabolism (with no additional food intake during this time).

    Time frame: Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28

  2. Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT

    The MMTT test involved the consumption of a standardised liquid meal (nutritional supplement of fat, carbohydrate, and protein)within 5 minutes. On Day -1 and on Day 28, following a minimum 10-hour fast, serial of blood samples were obtained prior and through 240 minutes after consumption of standardized meal for the measurement of glucose metabolism (with no additional food intake during this time).

    Time frame: Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience(immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)

  2. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Reported as TEAEs

    Number of participants with abnormal 12-lead ECG reported as TEAEs are reported.

    Time frame: Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)

  3. Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Number of participants with abnormal vital signs reported as TEAEs are reported.

    Time frame: Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)

  4. Number of Participants With Abnormal Physical Examinations Reported as TEAEs

    Number of participants with abnormal physical examinations reported as TEAEs are reported.

    Time frame: Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)

  5. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

    Time frame: Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)

  6. Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of MEDI0382

    Area under the plasma concentration time curve from time zero to infinity (AUC \[0-∞\]) of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  7. Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of Dapagliflozin

    Area under the plasma concentration time curve from time zero to infinity (AUC \[0-∞\]) of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  8. Area Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of MEDI0382

    Area under the plasma concentration-time curve during the dosing period (AUCtau) of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  9. Area Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of Dapagliflozin

    Area under the plasma Concentration-time curve during the dosing period (AUCtau) of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  10. Maximum Observed Serum Concentration (Cmax) of MEDI0382

    Maximum observed serum concentration (Cmax) of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  11. Maximum Observed Serum Concentration (Cmax) of Dapagliflozin

    Maximum observed serum concentration (Cmax) of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  12. Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI0382

    Time to reach maximum observed serum concentration (Tmax) of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  13. Time to Reach Maximum Observed Serum Concentration (Tmax) of Dapagliflozin

    Time to reach maximum observed serum concentration (Tmax) of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  14. Terminal Elimination Half-life (t½) of MEDI0382

    Terminal half-life is the time required for the plasma concentration to fall by 50% during the terminal phase. The t½ of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  15. Terminal Elimination Half-life (t½) of Dapagliflozin

    Terminal half-life is the time required for the plasma concentration to fall by 50% during the terminal phase. The t½ of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  16. Apparent Clearance (CL/F) of MEDI0382

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The CL/F of MEDI0382 is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28

  17. Apparent Clearance (CL/F) of Dapagliflozin

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The CL/F of Dapagliflozin is reported.

    Time frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28

  18. Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI0382

    Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI0382 are reported.

    Time frame: Day 1 (pre-dose), on Day 29 , and 28 days post last dose (end of study visit; approximately 8 weeks)

  19. Change From Baseline in Plasma Glucose AUC24-hrs to the End of Each Dosing Level as Measured by Continuous Glucose Monitoring (CGM)

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  20. Change From Baseline in Mean 24-hrs Plasma Glucose to the End of Each Dosing Level as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  21. Change From Baseline in Standard Deviation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  22. Change From Baseline in Coefficient of Variation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  23. Change From Baseline in Mean Amplitude of Glucose Excursions (MAGE) of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  24. Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Euglycemic Range to the End of Each Dosing as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Euglycemic range is defined as glucose levels of \>= 70 mg/dL (\>= 3.9 mmol/L) and \<= 180 mg/dL (\<= 10.0 mmol/L).

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  25. Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hyperglycemic Range to the End of Each Dosing as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Hyperglycemic (high glucose) range is defined as glucose levels of \> 180 mg/dL (\> 10.0 mmol/L).

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  26. Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hypoglycemic Range to the End of Each Dosing as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Hypoglycemic range is defined as glucose levels of \< 70 mg/dL (\< 3.9 mmol/L).

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

  27. Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM

    Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Clinically significant hypoglycemic range is defined as glucose levels of \< 54 mg/dL (3.0 mmol/L).

    Time frame: Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg

06

Results

Posted Jan 13, 2020

Participant flow

The study was conducted in Germany and Hungary between 08May2018 and 06Dec2018.

Participant flow — Overall Study
MilestonePlaceboMEDI0382
Started2425
Completed2423
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Other01

Outcome measures

PrimaryChange From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT)

The MMTT test involved the consumption of a standardised liquid meal (nutritional supplement of fat, carbohydrate, and protein) within 5 minutes. On Day -1 and on Day 28, following a minimum 10 hour fast, serial of blood samples were obtained prior and through 240 minutes after consumption of standardized meal for the measurement of glucose metabolism (with no additional food intake during this time).

Time frame:
Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28
Reported as:
Least squares mean · hr·mg/dL
Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT)
hr·mg/dLPlaceboMEDI0382
Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT)-11.28 (-51.05 to 28.50)-154.37 (-192.45 to -116.29)
Statistical analysis
  • Placebo vs MEDI0382 · ANCOVA · p = <0.0001 · Ls mean difference: -143.09 · 95% CI -198.20 to -87.98
PrimaryPercent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT

The MMTT test involved the consumption of a standardised liquid meal (nutritional supplement of fat, carbohydrate, and protein)within 5 minutes. On Day -1 and on Day 28, following a minimum 10-hour fast, serial of blood samples were obtained prior and through 240 minutes after consumption of standardized meal for the measurement of glucose metabolism (with no additional food intake during this time).

Time frame:
Zero minutes before and 15, 30, 45, 60, 90, 120, 180, and 240 minutes after consumption of the standardised meal on Day -1 (Baseline) and Day 28
Reported as:
Least squares mean · Percent change in Glucose AUC0-4hrs
Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT
Percent change in Glucose AUC0-4hrsPlaceboMEDI0382
Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT-0.13 (-5.96 to 5.69)-22.30 (-27.88 to -16.73)
Statistical analysis
  • Placebo vs MEDI0382 · ANCOVA · p = <0.0001 · Ls mean difference: -22.17 · 95% CI -30.24 to -14.10
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience(immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI0382
TEAEs1413
TESAEs00
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG) Reported as TEAEs

Number of participants with abnormal 12-lead ECG reported as TEAEs are reported.

Time frame:
Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Reported as TEAEs
ParticipantsPlaceboMEDI0382
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Reported as TEAEs00
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs

Number of participants with abnormal vital signs reported as TEAEs are reported.

Time frame:
Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs
ParticipantsPlaceboMEDI0382
Tachycardia21
Tachycardia paroxysmal10
Palpitations01
SecondaryNumber of Participants With Abnormal Physical Examinations Reported as TEAEs

Number of participants with abnormal physical examinations reported as TEAEs are reported.

Time frame:
Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Physical Examinations Reported as TEAEs
ParticipantsPlaceboMEDI0382
Number of Participants With Abnormal Physical Examinations Reported as TEAEs00
SecondaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

Time frame:
Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
ParticipantsPlaceboMEDI0382
Hypoglycemia10
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of MEDI0382

Area under the plasma concentration time curve from time zero to infinity (AUC \[0-∞\]) of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Geometric mean · ng.hr/mL
Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of MEDI0382
ng.hr/mLMEDI0382
Day 7 (MEDI0382 100 µg)106.4 (57.7 to 251.8)
Day 14 ( MEDI0382 200 µg)196.7 (99.4 to 472.0)
Day 28 (MEDI0382 300 µg)314.6 (211.0 to 537.3)
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of Dapagliflozin

Area under the plasma concentration time curve from time zero to infinity (AUC \[0-∞\]) of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Geometric mean · ng.hr/mL
Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC [0-∞]) of Dapagliflozin
ng.hr/mLPlaceboMEDI0382
Day -1432.6 (271.5 to 918.6)473.8 (288.8 to 1073.2)
Day 7410.2 (209.9 to 1024.2)438.0 (222.2 to 833.6)
Day 14421.0 (219.0 to 1327.8)448.6 (247.0 to 615.9)
Day 28405.7 (261.1 to 799.5)523.4 (319.5 to 946.0)
SecondaryArea Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of MEDI0382

Area under the plasma concentration-time curve during the dosing period (AUCtau) of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Geometric mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of MEDI0382
ng.hr/mLMEDI0382
Day 7 (MEDI0382 100 µg)89.6 (43.1 to 199.4)
Day 14 ( MEDI0382 200 µg)165.0 (86.9 to 365.5)
Day 28 (MEDI0382 300 µg)265.9 (101.7 to 795.1)
SecondaryArea Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of Dapagliflozin

Area under the plasma Concentration-time curve during the dosing period (AUCtau) of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Geometric mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve During the Dosing Period (AUCtau) of Dapagliflozin
ng.hr/mLPlaceboMEDI0382
Day -1400.9 (182.4 to 1011.5)430.3 (252.5 to 815.2)
Day 7377.5 (76.4 to 910.7)406.8 (211.5 to 1142.6)
Day 14417.1 (209.0 to 1107.7)396.8 (215.4 to 669.7)
Day 28423.1 (180.6 to 977.3)463.8 (284.3 to 1245.7)
SecondaryMaximum Observed Serum Concentration (Cmax) of MEDI0382

Maximum observed serum concentration (Cmax) of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentration (Cmax) of MEDI0382
ng/mLMEDI0382
Day 7 (MEDI0382 100 µg)5.2 (2.7 to 11.9)
Day 14 ( MEDI0382 200 µg)10.1 (4.4 to 21.7)
Day 28 (MEDI0382 300 µg)17.2 (6.1 to 45.4)
SecondaryMaximum Observed Serum Concentration (Cmax) of Dapagliflozin

Maximum observed serum concentration (Cmax) of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentration (Cmax) of Dapagliflozin
ng/mLPlaceboMEDI0382
Day -1110.1 (46.3 to 208.3)116.7 (38.2 to 206.8)
Day 792.0 (5.2 to 256.7)84.4 (24.1 to 211.7)
Day 1495.6 (33.5 to 280.7)61.1 (15.8 to 149.9)
Day 28112.2 (47.0 to 235.4)94.2 (25.2 to 182.2)
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of MEDI0382

Time to reach maximum observed serum concentration (Tmax) of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Median · Hours
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI0382
HoursMEDI0382
Day 7 (MEDI0382 100 µg)5.5 (2 to 8)
Day 14 ( MEDI0382 200 µg)5.1 (2 to 8)
Day 28 (MEDI0382 300 µg)4 (1.9 to 8.1)
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of Dapagliflozin

Time to reach maximum observed serum concentration (Tmax) of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Median · Hours
Time to Reach Maximum Observed Serum Concentration (Tmax) of Dapagliflozin
HoursPlaceboMEDI0382
Day -11 (0.5 to 2)1 (0.4 to 23.9)
Day 71 (0.5 to 11.4)1 (0.5 to 4)
Day 141.1 (0.5 to 6)1 (0 to 8.1)
Day 281 (0.2 to 1.8)1 (0.5 to 8.1)
SecondaryTerminal Elimination Half-life (t½) of MEDI0382

Terminal half-life is the time required for the plasma concentration to fall by 50% during the terminal phase. The t½ of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Geometric mean · Hours
Terminal Elimination Half-life (t½) of MEDI0382
HoursMEDI0382
Day 7 (MEDI0382 100 µg)8.8 (6.1 to 11.9)
Day 14 ( MEDI0382 200 µg)9 (5.6 to 11.8)
Day 28 (MEDI0382 300 µg)9.1 (5.1 to 11.6)
SecondaryTerminal Elimination Half-life (t½) of Dapagliflozin

Terminal half-life is the time required for the plasma concentration to fall by 50% during the terminal phase. The t½ of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Geometric mean · Hours
Terminal Elimination Half-life (t½) of Dapagliflozin
HoursPlaceboMEDI0382
Day -18.2 (5.3 to 11.2)7.8 (5.4 to 11.3)
Day 77.9 (4.1 to 10.4)8.3 (5.8 to 11.1)
Day 147.0 (5.1 to 11.4)8.5 (7 to 10)
Day 287.6 (5.8 to 11.0)9.1 (6.1 to 11.8)
SecondaryApparent Clearance (CL/F) of MEDI0382

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The CL/F of MEDI0382 is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days 7, 14, and 28
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of MEDI0382
L/hrMEDI0382
Day 7 (MEDI0382 100 µg)1.1 (0.5 to 1.9)
Day 14 ( MEDI0382 200 µg)1.3 (0.5 to 2.2)
Day 28 (MEDI0382 300 µg)1.2 (0.8 to 1.8)
SecondaryApparent Clearance (CL/F) of Dapagliflozin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The CL/F of Dapagliflozin is reported.

Time frame:
Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hrs post-dose on Days -1, 7, 14, and 28
Reported as:
Geometric mean · L/Hr
Apparent Clearance (CL/F) of Dapagliflozin
L/HrPlaceboMEDI0382
Day -125.5 (13.3 to 38.9)23.3 (12.3 to 39.6)
Day 726.7 (11.0 to 52.8)25.7 (14.2 to 47.3)
Day 1425.9 (9.0 to 47.7)25.5 (18.8 to 46.4)
Day 2826.8 (13.8 to 40.2)22.2 (13.4 to 35.2)
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI0382

Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI0382 are reported.

Time frame:
Day 1 (pre-dose), on Day 29 , and 28 days post last dose (end of study visit; approximately 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI0382
ParticipantsPlaceboMEDI0382
Day 103
Day 2901
End of Study12
SecondaryChange From Baseline in Plasma Glucose AUC24-hrs to the End of Each Dosing Level as Measured by Continuous Glucose Monitoring (CGM)

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · hr.mg/dL
Change From Baseline in Plasma Glucose AUC24-hrs to the End of Each Dosing Level as Measured by Continuous Glucose Monitoring (CGM)
hr.mg/dLPlaceboMEDI0382
Day 7 (MEDI0382 100 μg)49.14 ± 667.30-832.66 ± 506.22
Day 14 (MEDI0382 200 μg)57.30 ± 379.95-666.05 ± 647.63
Day 28 (MEDI0382 300 μg)229.47 ± 589.19-726.85 ± 710.71
SecondaryChange From Baseline in Mean 24-hrs Plasma Glucose to the End of Each Dosing Level as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · mg/dL
Change From Baseline in Mean 24-hrs Plasma Glucose to the End of Each Dosing Level as Measured by CGM
mg/dLPlaceboMEDI0382
Day 7 (MEDI0382 100 μg)2.59 ± 28.96-34.74 ± 20.34
Day 14 (MEDI0382 200 μg)2.83 ± 17.01-28.34 ± 27.12
Day 28 (MEDI0382 300 μg)9.70 ± 24.73-30.55 ± 29.82
SecondaryChange From Baseline in Standard Deviation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · mg/dL
Change From Baseline in Standard Deviation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM
mg/dLPlaceboMEDI0382
Day 7 (MEDI0382 100 μg)-3.01 ± 13.84-7.21 ± 11.05
Day 14 (MEDI0382 200 μg)1.38 ± 9.47-7.52 ± 9.73
Day 28 (MEDI0382 300 μg)-4.39 ± 10.67-9.76 ± 10.18
SecondaryChange From Baseline in Coefficient of Variation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · Percent of coefficient of variation
Change From Baseline in Coefficient of Variation of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM
Percent of coefficient of variationPlaceboMEDI0382
Day 7 (MEDI0382 100 μg)-2.37 ± 9.06-0.45 ± 6.68
Day 14 (MEDI0382 200 μg)0.96 ± 8.74-2.06 ± 6.59
Day 28 (MEDI0382 300 μg)-4.26 ± 7.16-3.21 ± 7.25
SecondaryChange From Baseline in Mean Amplitude of Glucose Excursions (MAGE) of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg.

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · mg/dL
Change From Baseline in Mean Amplitude of Glucose Excursions (MAGE) of 24-hrs Plasma Glucose Readings to the End of Each Dosing Level as Measured by CGM
mg/dLPlaceboMEDI0382
Day 7 (MEDI0382 100 μg)-13.46 ± 32.07-25.74 ± 35.06
Day 14 (MEDI0382 200 μg)18.05 ± 47.60-26.59 ± 25.60
Day 28 (MEDI0382 300 μg)-8.09 ± 27.68-27.92 ± 23.17
SecondaryChange From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Euglycemic Range to the End of Each Dosing as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Euglycemic range is defined as glucose levels of \>= 70 mg/dL (\>= 3.9 mmol/L) and \<= 180 mg/dL (\<= 10.0 mmol/L).

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · Percent of Euglycemic Range
Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Euglycemic Range to the End of Each Dosing as Measured by CGM
Percent of Euglycemic RangePlaceboMEDI0382
Day 7 (MEDI0382 100 μg)-5.61 ± 19.657.12 ± 20.60
Day 14 (MEDI0382 200 μg)-2.79 ± 10.165.31 ± 17.71
Day 28 (MEDI0382 300 μg)-4.17 ± 15.806.54 ± 24.37
SecondaryChange From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hyperglycemic Range to the End of Each Dosing as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Hyperglycemic (high glucose) range is defined as glucose levels of \> 180 mg/dL (\> 10.0 mmol/L).

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · Percent of hyperglycemic range
Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hyperglycemic Range to the End of Each Dosing as Measured by CGM
Percent of hyperglycemic rangePlaceboMEDI0382
Day 7 (MEDI0382 100 μg)3.62 ± 17.80-13.99 ± 14.95
Day 14 (MEDI0382 200 μg)0.36 ± 10.50-9.81 ± 13.68
Day 28 (MEDI0382 300 μg)6.08 ± 16.96-9.72 ± 20.97
SecondaryChange From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hypoglycemic Range to the End of Each Dosing as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Hypoglycemic range is defined as glucose levels of \< 70 mg/dL (\< 3.9 mmol/L).

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · Percent of hypoglycemic range
Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within the Hypoglycemic Range to the End of Each Dosing as Measured by CGM
Percent of hypoglycemic rangePlaceboMEDI0382
Day 7 (MEDI0382 100 μg)1.17 ± 5.646.08 ± 10.36
Day 14 (MEDI0382 200 μg)2.00 ± 3.793.44 ± 12.72
Day 28 (MEDI0382 300 μg)-2.08 ± 4.142.84 ± 12.20
SecondaryChange From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM

Continuous glucose monitoring is a minimally invasive device applied to the skin in the upper arm that provides a measure of interstitial glucose levels every 15 minutes. Continuous glucose monitoring measures glucose excursions during different meals and at different times of the day. End of dosing: Day 7 for MEDI0382 100 μg; Day 14 for MEDI0382 200 μg; and Day 28 for MEDI0382 300 μg. Clinically significant hypoglycemic range is defined as glucose levels of \< 54 mg/dL (3.0 mmol/L).

Time frame:
Day -1 (Baseline) through Day 7 for MEDI0382 100 μg, Day 14 for MEDI0382 200 μg, and Day 28 for MEDI0382 300 μg
Reported as:
Mean · Percent of hypoglycemic range
Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM
Percent of hypoglycemic rangePlaceboMEDI0382
Day 7 (MEDI0382 100 μg)0.76 ± 3.641.61 ± 5.03
Day 14 (MEDI0382 200 μg)0.27 ± 1.19-0.06 ± 2.18
Day 28 (MEDI0382 300 μg)-0.26 ± 0.900.93 ± 4.91

Adverse events

Collected over Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)0/24 (0%)14/24 (58.3%)
MEDI03820/25 (0%)0/25 (0%)13/25 (52%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlaceboMEDI0382
NauseaGastrointestinal disorders2/245/25
VomitingGastrointestinal disorders0/245/25
HeadacheNervous system disorders1/245/25
Viral upper respiratory tract infectionInfections and infestations3/243/25
Abdominal pain upperGastrointestinal disorders0/243/25
ConstipationGastrointestinal disorders0/243/25
TachycardiaCardiac disorders2/241/25
DiarrhoeaGastrointestinal disorders2/241/25
HyperhidrosisSkin and subcutaneous tissue disorders2/240/25
DizzinessNervous system disorders0/242/25

Baseline characteristics

As-treated population included all participants who received any dose of study drugs and analyzed according to the treatment they actually received.

Age, Continuous
Age, Continuous(Years)PlaceboMEDI0382TOTAL
Mean58.4 ± 10.061.0 ± 8.259.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI0382TOTAL
Female121022
Male121527
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMEDI0382TOTAL
Hispanic or Latino101
Not Hispanic or Latino232548
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMEDI0382TOTAL
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White242549
More than one race000
Unknown or Not Reported000
07

Study locations

8 sites
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    München, 81241, Germany
  • Research Site
    Balatonfüred, 8230, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Szeged, 6720, Hungary
  • Research Site
    Manchester, M13 9NQ, United Kingdom
  • Research Site
    Rotherham, S65 1DA, United Kingdom
08

References and documents

Study documents

  • Study protocol · Sep 19, 2017
  • Statistical analysis plan · Jul 3, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Registry details

Key details

Study ID
NCT03444584
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
May 8, 2018
Primary completion
Dec 6, 2018
Completion
Dec 6, 2018
Results posted
Jan 13, 2020
Last update
Jan 13, 2020

Study contacts

Stephen Bain, MD
principal investigator · Joint Clinical Research Facility

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus→

Other studies from this sponsor

MedImmune LLC

Start the discussion